Ipamorelin and CJC-1295 are two of the most-referenced peptides in growth-hormone research — and they're studied together so often that they're sold as a blend. But they're different molecules that work through different mechanisms. Here's the clear breakdown.
The quick answer
Ipamorelin is a selective growth-hormone secretagogue (a ghrelin-receptor agonist). CJC-1295 is a GHRH analogue — a stabilised version of growth-hormone-releasing hormone. They act on two different receptors in the growth-hormone axis, which is exactly why researchers combine them.
Why they're studied together
The growth-hormone axis responds to two signals: a "releasing" signal (GHRH) and a secretagogue signal (via the ghrelin receptor). CJC-1295 covers the first, Ipamorelin the second. Because they hit complementary pathways, they're frequently studied as a pair — which is why the CJC-1295 / Ipamorelin blend exists as a single product.
Side-by-side
- Type: Ipamorelin = selective GH secretagogue (pentapeptide); CJC-1295 = GHRH analogue
- Receptor: Ipamorelin = ghrelin receptor (GHS-R); CJC-1295 = GHRH receptor
- Studied for: both appear in growth-hormone axis and recovery/body-composition research
- Selectivity: Ipamorelin is valued in research for being selective — acting without stimulating other hormones
- Handling: both are lyophilised powders — store at −20°C, reconstitute with bacteriostatic water, refrigerate once mixed
Sourcing in Australia
We hold Ipamorelin and the CJC-1295 / Ipamorelin blend in Australian stock, independently batch-tested with published Certificates of Analysis, dispatched same or next business day. See the lab results in our CoA Library, and the wider context in our complete guide to research peptides in Australia.
Shop growth-hormone research peptides
All products are supplied strictly for laboratory and in-vitro research use only. Not for human or veterinary consumption. This article describes fields of scientific research and is not medical advice or a claim about effects in humans.